Objective Betalin’s mission is to provide a tissue-derived acellular micro-scaffold that will extend the life and the insulin-producingperformance of transplanted beta cells in order to reduce or eliminate the dependence of some diabetics on insulin therapy.Type 1 Diabetes is a chronic disease that results from the autoimmune destruction of the insulin-producing beta cells in thepancreas. Its cause is still uncertain and there is no known way to prevent its onset. With~70,000 new cases diagnosedeach year, it is estimated that ~17 mn people worldwide are afflicted with T1DM. In the US alone, T1DM results in $14.4 bnin medical costs and lost income annually. Type 1 diabetics face a lifetime regime of insulin therapy and very careful lifestylemanagement in an attempt to mitigate the long-term complications associated with T1DM such as cardiovascular disease,damage to the eyes, kidneys and nerves, and premature death. In recent years islet transplantation has been researched asa treatment for T1DM. The procedure involves injecting millions of islets (the pancreatic cell clusters that “house” theinsulinproducingbeta cells) harvested from cadavers, followed by immunosuppression therapy. Islet transplantation is a promisingapproach but the naked islets are very unstable: they must be transplanted almost immediately after harvesting and up to80% of the transplanted islets stop functioning within 24hrs. The result is that, after five years, less than 10% of therecipients are free of daily insulin treatment. Betalin’s technology is based on the premise that in order for beta cells tofunction properly it is necessary to provide an appropriate stromal (connective tissue) micro-environment. The proprietaryplatform technology is a method to prepare acellular organ-derived micro-scaffolds that preserve the architecture and thebasic composition of organ stroma and ensure that no seeded cell will be more than 150 microns from a source of nutrientsand gases. Fields of science medical and health sciencesclinical medicineendocrinologydiabetesdiabetic nephropathymedical and health sciencesbasic medicineimmunologymedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesclinical medicineophthalmologyretinopathymedical and health sciencesclinical medicineangiologyvascular diseasescerebrovascular diseases Programme(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) SMEInst-02-2016-2017 - Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator BETALIN THERAPEUTICS LTD Net EU contribution € 50 000,00 Address 3 menachem begin 5268101 Ramat gam Israel See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00